Determining whether to invest in LENZ Therapeutics requires balancing the significant long-term growth potential of its FDA-approved ophthalmic portfolio against the commercial execution risks and cash burn typical of emerging pharmaceutical companies. While institutional analysts highlight its innovative product differentiation in treating presbyopia, prospective investors must carefully evaluate their individual risk tolerance and portfolio diversification strategies before committing capital.